A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients

• Status: Completed
• Trial end date: 2003-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for emergency treatment of patients with schizophrenia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Pharmaceutica N.V., Belgium
• Treatments: Lorazepam; Risperidone

Criteria

Inclusion Criteria:

• Psychotic patients with schizophrenia who require rapid intervention

• experiencing symptoms of a psychotic disorder

• capable of choosing to be treated

Exclusion Criteria:

• Patients with a known hypersensitivity to the study drugs

• have participated in an investigational drug trial within 30 days of study initiation

• known to be unresponsive to treatment with risperidone or the comparator drug

• known to have benzodiazepine dependence (addiction to this class of anti-anxiety drugs)